Glucotrack director resigns citing conflict of interest, CEO details LT-100 plans

Glucotrack, Inc. disclosed in a Form 8-K that Paul V. Goode notified the Board of Directors of Glucotrack, Inc. of his resignation from the Board, effective immediately, on September 14, 2026.¹

In his resignation notice, Goode said he had concluded that a potential conflict of interest existed between the company and its subsidiary, tied to ongoing discussions over how duties, rights, and obligations of the relevant entities would be carried out under the merger agreement that closed Glucotrack's business combination with Lokahi Therapeutics, Inc.¹ The company said it had given Goode a copy of its disclosures before filing the 8-K and offered him the chance to submit a letter stating whether he agreed with the company's account, with any such letter to be filed as an exhibit within two business days of receipt.¹ The resignation notice itself was filed as Exhibit 17.1.

Separately, on September 23, 2026, Glucotrack and Lokahi Therapeutics issued a shareholder update from CEO Erik Emerson. He noted that the companies completed their strategic business combination on July 14, and have since been working through post-closing matters including conversion of the Series A convertible preferred stock, which remains subject to Nasdaq requirements and other conditions.²

On the pipeline, Emerson said LT-100 is a biologic development program for osteoarthritis knee pain, with regulatory, clinical, manufacturing, and operational activities underway; a clinical protocol has been submitted for regulatory review, and the company is targeting study initiation in the near term, subject to regulatory feedback.² The planned study will evaluate safety and efficacy of LT-100 given by subcutaneous injection, comparing once-weekly subcutaneous administration to the historical regimen of 15 weekly intradermal injections.²